Jinhe Historical Cash Flow

002688 Stock   4.52  0.04  0.89%   
Analysis of Jinhe Biotechnology cash flow over time is an excellent tool to project Jinhe Biotechnology future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Capital Expenditures of 480.1 M or Total Cash From Operating Activities of 169.2 M as it is a great indicator of Jinhe Biotechnology ability to facilitate future growth, repay debt on time or pay out dividends.
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Jinhe Biotechnology latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Jinhe Biotechnology is a good buy for the upcoming year.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Jinhe Biotechnology Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

About Jinhe Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Jinhe balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Jinhe's non-liquid assets can be easily converted into cash.

Jinhe Biotechnology Cash Flow Chart

At present, Jinhe Biotechnology's Capital Expenditures is projected to increase significantly based on the last few years of reporting. The current year's Net Income is expected to grow to about 111 M, whereas Other Cashflows From Financing Activities is projected to grow to (354.7 M).

Dividends Paid

The total amount of dividends that a company has paid out to its shareholders over a specific period.

Capital Expenditures

Capital Expenditures are funds used by Jinhe Biotechnology to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Jinhe Biotechnology operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Jinhe Biotechnology financial statement analysis. It represents the amount of money remaining after all of Jinhe Biotechnology Co operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Change To Inventory

The increase or decrease in the amount of inventory a company has over a certain period.

Net Borrowings

The difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period.
Most accounts from Jinhe Biotechnology's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Jinhe Biotechnology current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Jinhe Biotechnology Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
At present, Jinhe Biotechnology's Capital Expenditures is projected to increase significantly based on the last few years of reporting. The current year's Net Income is expected to grow to about 111 M, whereas Other Cashflows From Financing Activities is projected to grow to (354.7 M).
 2021 2022 2023 2024 (projected)
Capital Expenditures383.7M402.2M457.2M480.1M
Dividends Paid104.3M40.5M148.7M90.5M

Jinhe Biotechnology cash flow statement Correlations

-0.02-0.76-0.31-0.190.190.450.78-0.410.540.120.78-0.4-0.070.710.35
-0.020.12-0.090.15-0.15-0.270.030.460.42-0.62-0.130.60.37-0.110.45
-0.760.120.410.06-0.19-0.47-0.680.68-0.38-0.11-0.770.640.42-0.67-0.04
-0.31-0.090.41-0.70.040.31-0.420.05-0.560.04-0.450.00.05-0.4-0.13
-0.190.150.06-0.7-0.24-0.320.010.430.33-0.51-0.10.480.17-0.10.07
0.19-0.15-0.190.04-0.24-0.250.09-0.340.20.250.44-0.26-0.1-0.280.36
0.45-0.27-0.470.31-0.32-0.250.42-0.34-0.05-0.10.27-0.36-0.210.56-0.07
0.780.03-0.68-0.420.010.090.42-0.180.75-0.10.89-0.170.150.820.51
-0.410.460.680.050.43-0.34-0.34-0.180.27-0.57-0.50.950.86-0.390.43
0.540.42-0.38-0.560.330.2-0.050.750.27-0.390.620.330.530.390.85
0.12-0.62-0.110.04-0.510.25-0.1-0.1-0.57-0.390.17-0.71-0.370.16-0.4
0.78-0.13-0.77-0.45-0.10.440.270.89-0.50.620.17-0.45-0.140.710.41
-0.40.60.640.00.48-0.26-0.36-0.170.950.33-0.71-0.450.78-0.420.51
-0.070.370.420.050.17-0.1-0.210.150.860.53-0.37-0.140.78-0.160.71
0.71-0.11-0.67-0.4-0.1-0.280.560.82-0.390.390.160.71-0.42-0.160.07
0.350.45-0.04-0.130.070.36-0.070.510.430.85-0.40.410.510.710.07
Click cells to compare fundamentals

Jinhe Biotechnology Account Relationship Matchups

Jinhe Biotechnology cash flow statement Accounts

201920202021202220232024 (projected)
Other Cashflows From Financing Activities34.3M103.9M83.6M(414.9M)(373.4M)(354.7M)
Dividends Paid222.8M222.9M104.3M40.5M148.7M90.5M
Capital Expenditures178.8M204.0M383.7M402.2M457.2M480.1M
Total Cash From Operating Activities282.2M258.1M153.0M124.5M198.8M169.2M
Net Income184.9M117.3M94.0M75.5M86.5M111.0M
Total Cash From Financing Activities(185.9M)27.6M448.7M150.4M135.4M129.8M
Change To Account Receivables8.6M(8.2M)(138.6M)(152.5M)(137.2M)(130.4M)
Change To Inventory(63.0M)(19.8M)(135.6M)(105.6M)11.5M12.1M
Investments(2.4M)(1.4M)(100K)(4.2M)(534.2M)(507.5M)
Change In Cash(86.3M)74.1M201.5M(90.3M)86.7M91.0M
Net Borrowings2.5M146.5M(334.1M)605.9M696.7M731.6M
Total Cashflows From Investing Activities(184.1M)(204.4M)(398.0M)(386.8M)(444.8M)(467.1M)
Depreciation99.4M120.0M131.9M155.9M179.3M116.8M
Change To Netincome98.1M98.9M107.6M66.3M76.2M79.2M
Change To Liabilities(47.5M)(61.9M)91.5M40.2M46.2M48.5M
End Period Cash Flow225.5M299.7M501.2M410.9M497.6M373.2M
Free Cash Flow103.3M54.1M(230.7M)(277.7M)(258.5M)(245.5M)
Change In Working Capital(92.3M)(80.1M)(182.7M)(217.9M)(166.2M)(174.5M)
Begin Period Cash Flow311.8M225.5M299.7M501.2M410.9M348.3M
Other Non Cash Items62.9M64.0M58.2M32.0M56.4M57.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Jinhe Stock

The Cash Flow Statement is a financial statement that shows how changes in Jinhe balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Jinhe's non-liquid assets can be easily converted into cash.